McKesson lifts annual profit forecast on plans to focus on high-margin businesses

McKesson (MCK) has raised its fiscal 2026 adjusted EPS forecast to $38.05-$38.55 and increased its long-term adjusted earnings growth target to 13%-16%, driven by a strategic focus on high-margin oncology and specialty drug distribution businesses. This positive outlook, following a recent business reorganization and strong operational track record, signals robust future growth compounding capabilities to analysts, despite ongoing investor concerns regarding drug pricing, and prompted a roughly 3% rise in shares.

Analysis

McKesson (MCK) has issued a significant upward revision to its financial outlook, signaling strong confidence in its strategic realignment towards higher-margin businesses. The company raised its fiscal 2026 adjusted earnings forecast to a range of $38.05-$38.55 per share and lifted its long-term adjusted earnings growth target to 13%-16% from a prior 12%-14%. This optimism is underpinned by a new organizational structure focused on a dedicated oncology and multispecialty unit, which is projected to be the firm's fastest-growing segment with 13%-16% annual growth, substantially outpacing the 5%-8% growth expected from its traditional North American drug distribution business. The strategy is further supported by M&A activity, such as the acquisition of a controlling stake in Core Ventures. The market has responded positively, with shares increasing approximately 3%, and analyst commentary from firms like Leerink Partners and Evercore ISI reinforces the view that the update signals enhanced future growth compounding capabilities. While the outlook is strong, investors remain focused on potential headwinds from drug pricing and await further details on the planned separation of the medical-surgical solutions unit, both of which are expected to be addressed during the company's investor day.

Key Decisions for Investors

• The upgraded guidance and strategic pivot towards the high-margin oncology segment, which is projected to grow at 13-16% annually, warrants a re-evaluation of McKesson's long-term earnings power and potential for sustained growth.
• Investors should closely monitor the upcoming investor day for management's commentary on navigating drug pricing pressures and for specific details regarding the planned separation of the medical-surgical solutions unit, as these are key outstanding variables.
• Given the positive market reaction, it is prudent to assess whether the new, higher growth trajectory is fully priced into the current valuation or if further upside remains, contingent on successful execution of the specialty and oncology strategy.